醫師介紹
醫師學術論文
Paper
學術機構典藏
論文
期刊論文
期刊論文/Journal Paper (作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄) |
日期 | |
1 | 許偉帆(Hsu, Wei-Fan)、陳春妃(Chuen-Fei Chen)*、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、陳昇弘(Chen, Sheng-Hung)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*,Trajectories and decline of serum hepatitis B surface antigen predict outcomes in patients with chronic hepatitis B,Open Forum Infectious Diseases,2024 Dec,11(12):ofae699 | 2024 . 12 |
2 | 王鴻偉(Hung-Wei Wang)、賴學洲(Hsueh-Chou Lai)*、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、陳浤燿(Hung-Yao Chen)、張哲維(Che-Wei Chang)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*,Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma,Journal of Gastrointestinal Oncology,2024 Sep,0(0):0-0 | 2024 . 09 |
3 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、陳昇弘(Chen, Sheng-Hung)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*,Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus,American Journal of Cancer Research,2024 Apr,14(4):1914-1925 | 2024 . 04 |
4 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、陳政國(Cheng-Kuo Chen)、王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蔡明宏(Ming-Hung Tsai)、陳昇弘(Chen, Sheng-Hung)、朱家聲(Chia-Sheng Chu)、蘇文邦(Wen-Pang Su)、周仁偉(Jen-Wei Chou)、高榮達(Jung-Ta Kao)、陳浤燿(Hung-Yao Chen)、莊世杰(Shih-Chieh Chuang)、蔡宗佑(Tsung-Yu Tsai)、蕭望德(Won-Der Shau)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*,Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy,American Journal of Cancer Research,2023 Feb,13(2):654-668 | 2023 . 02 |
5 | 許偉帆(Hsu, Wei-Fan)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Hung-Yao Chen)、王鴻偉(Hung-Wei Wang)、黃冠棠(Guan-Tarn Huang)、彭成元(Peng, Cheng-Yuan)*,Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents,JOURNAL OF VIRAL HEPATITIS,2022 Jun,29():01-10 | 2022 . 06 |
6 | 許偉帆(Hsu, Wei-Fan)、王鴻偉(Hung-Wei Wang)、陳政國(Cheng-Kuo Chen)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蔡明宏(Ming-Hung Tsai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、朱家聲(Chia-Sheng Chu)、周仁偉(Jen-Wei Chou)、陳昇弘(Chen, Sheng-Hung)、蔡宗佑(Tsung-Yu Tsai)、蕭望德(Won-Der Shau)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、彭成元(Peng, Cheng-Yuan)*,Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies,American Journal of Cancer Research,2021 Dec,11(12):6173-6187 | 2021 . 12 |
7 | 王鴻偉(Hung-Wei Wang)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、許偉帆(Hsu, Wei-Fan)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)*,On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma,Cancers,2021 Jul,13(15):3758 | 2021 . 07 |
8 | 許偉帆(Hsu, Wei-Fan)、莊伯恒(Po-Heng Chuang)、陳政國(Cheng-Kuo Chen)、王鴻偉(Hung-Wei Wang)、蔡明宏(Ming-Hung Tsai)、蘇文邦(Wen-Pang Su)、陳浤燿(Hung-Yao Chen)、楊其穎(Chi-Ying Yang)、林俊哲(LIN CHUN-CHE)、黃冠棠(Guan-Tarn Huang)、林肇堂(LIN JAW-TOWN)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)*,Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience,American Journal of Cancer Research,2020 Dec,10(12):4547-4560 | 2020 . 12 |
9 | 陳昇弘(Sheng-Hung Chen)、賴學洲(Hsueh-Chou Lai)、江宜平(I-Ping Chiang)、蘇文邦(Wen-Pang Su)、林佳欣(Chia-Hsin Lin)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Hung-Yao Chen)、黃冠棠(Guan-Tarn Huang)、彭成元(Cheng-Yuan Peng)*,Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients With Chronic Hepatitis C After Viral Eradication,CLINICAL INFECTIOUS DISEASES,2020 Jan,70(1):114-122 | 2020 . 01 |
10 | 許偉帆(Wei-Fan Hsu)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)*、林佳欣(Chia-Hsin Lin)、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳浤燿(Hung-Yao Chen)、王鴻偉(Hung-Wei Wang)、黃冠棠(Guan-Tarn Huang)、彭成元(Cheng-Yuan Peng)*,Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents,BMC GASTROENTEROLOGY,2019 Apr,19(1):63 | 2019 . 04 |
11 | 許偉帆(Wei-Fan Hsu)、陳春妃(Chuen-Fei Chen)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Chen, Ching-Hsiang)、王鴻偉(Hung-Wei Wang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*,Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy,LIVER INTERNATIONAL,2018 Apr,38(4):627-635 | 2018 . 04 |
12 | 陳昇弘(Chen, Sheng-Hung)、賴學洲(Lai, Hsueh-Chou)、江宜平(Chiang, I-Ping)、蘇文邦(Wen-Pang Su)、林佳欣、高榮達(Kao, Jung-Ta)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Chen, Ching-Hsiang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*,Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C,PLoS One,2018 Jan,13(1):e0190455-e0190455 | 2018 . 01 |
13 | 王鴻偉(Hung-Wei Wang)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen)、許偉帆(Wei-Fan Hsu)、黃冠棠,New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis,Scientific Reports,2017 Jun,7(1):3259 | 2017 . 06 |
研討會論文
研討會論文/Conference Papers (發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目) |
日期 | |
1 | Long-term dynamic changes of insulin resistance and lipid profiles in patients with hepatitis C viral eradication,2024TDDW台灣消化醫學週,高雄萬豪飯店,2024.10.04~2024.10.06, | 2024 . 10 |
2 | Components of Cardiometabolic Criteria Predict Liver-Related Events in Patients Cured of Hepatitis C Virus,2024 Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation,台中金典酒店,2024.05.18~2024.05.19, | 2024 . 05 |
3 | The Impact of Steatotic Liver Disease on Liver-Related Events in Patients Cured of Hepatitis C Virus,2024 The Asian Pacific Association for the Study of the Liver Annual Meeting,Kyoto International Conference Hall,2024.03.27~2024.03.31, | 2024 . 03 |
4 | Metabolic dysfunction but not echo liver steatosis increases the risk of liver related events in patients with cured hepatitis C,中華民國一一二年台灣消化系聯合學術演講年會,台北榮民總醫院,2023.03.25~2023.03.26, | 2023 . 03 |
5 | B型肝炎表面抗原軌跡與抗原下降預測長期接受核苷酸類似物治療慢性B型肝炎患者療效,中華民國一一二年台灣消化系聯合學術演講年會,台北榮民總醫院,2023.03.25~2023.03.26, | 2023 . 03 |
6 | Trajectories of Serum Hepatitis B Surface Antigen Kinetics and Surface Antigen Decline Predict Treatment Outcomes in Patients with Chronic Hepatitis B Receiving Long-term Nucleos(t)ide Analogue Therapy,2023 The Asian Pacific Association for the Study of the Liver Annual Meeting,台北國際會議中心(TICC),2023.02.15~2023.02.19, | 2023 . 02 |
7 | Metabolic Dysfunction but Not Ultrasonographic Hepatic Steatosis Increases the Risk of Liver-Related Events in Patients with Cured Hepatitis C,2023 The Asian Pacific Association for the Study of the Liver Annual Meeting,台北國際會議中心(TICC),2023.02.15~2023.02.19, | 2023 . 02 |
8 | Concurrent immune checkpoint inhibitor and tyrosine kinase inhibitor therapy yields better outcome than immune checkpoint inhibitor monotherapy in patients with advanced hepatocellular carcinoma,2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma,台大醫院國際會議中心,2022.06.23~2022.06.25, | 2022 . 06 |
9 | Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver related complications in patients with chronic hepatitis C receiving direct acting antiviral agents,2022 Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatocellular Carcinoma,台大醫院國際會議中心,2022.06.23~2022.06.25, | 2022 . 06 |
10 | Post-therapeutic nonalcoholic fatty liver disease fibrosis scores predicts liver-related complications in chronic hepatitis C patients receiving oral agents,中華民國一一一年台灣消化系聯合學術演講年會,高雄萬豪飯店,2022.03.26~2022.03.27, | 2022 . 03 |
11 | Clinical characteristics of patients receiving hepatitis B viral chemoprophylaxis after the implementation of expanded reimbursement criteria,中華民國一一一年台灣消化系聯合學術演講年會,高雄萬豪飯店,2022.03.26~2022.03.27, | 2022 . 03 |
12 | Concurrent immune checkpoint inhibitor and tyrosine kinase inhibitor therapy yields better outcome than immune checkpoint inhibitor monotherapy in patients with advanced hepatocellular carcinoma,2021TDDW台灣消化醫學週,台大醫院國際會議中心,2021.09.25~2021.09.26, | 2021 . 09 |
13 | Nivolumab therapy with and without combination of tyrosine kinase inhibitor for patients with unresectable hepatocellular carcinoma,中華民國一一O年台灣消化系聯合學術演講年會,中國醫藥大學英才校區,2021.03.27~2021.03.28, | 2021 . 03 |
14 | Baseline albumin-total bilirubin (ALBI) score predicts incident or recurrent hepatocellular carcinoma in chronic hepatitis C patients receiving direct-acting antiviral agents,中華民國一一O年台灣消化系聯合學術演講年會,中國醫藥大學英才校區,2021.03.27~2021.03.28, | 2021 . 03 |
15 | Longitudinal changes in acoustic radiation force impulse (ARFI) values in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy,中華民國一一O年台灣消化系聯合學術演講年會,中國醫藥大學英才校區,2021.03.27~2021.03.28, | 2021 . 03 |
16 | 周產期及停經後的婦女患有原發性肝惡性腫瘤有較差的預後嗎?來自台灣全國性的世代研究證據,中華民國110年消化系聯合學術演講年會,中國醫藥大學,2021.03.27~2021.03.28, | 2021 . 03 |
17 | 新診斷2型糖尿病患者化膿性肝膿瘍的風險:台灣全國性的世代研究,中華民國110年消化系聯合學術演講年會,中國醫藥大學,2021.03.27~2021.03.28, | 2021 . 03 |
18 | Outcome of HCV infected prisoners under direct-acting antiviral agent treatment in Taiwan.,2020TDDW台灣消化醫學週,台大醫院國際會議中心,2020.09.25~2020.09.27, | 2020 . 09 |
19 | Post-treatment liver stiffness measurement using acoustic radiation force impulse predicts incident hepatocellular carcinoma in chronic hepatitis C patients with advanced liver fibrosis,2020台灣消化系醫學週,台大醫院國際會議中心,2020.09.26~2020.09.27, | 2020 . 09 |
20 | Longitudinal Analyses of the Biphasic Kinetics in Liver and Spleen Stiffness Values in Hepatitis C Virus-Infected Patients on and off Direct-Acting Antiviral Therapies 分析接受Direct-Acting Antivirals治療之C型肝炎病患治療中及治療後肝臟及脾臟硬度跨越時間之雙相變化,Taiwan Digestive Disease Week (TDDW) 2020,National Taiwan University Hospital International Convention Center,2020.09.25~2020.09.27, | 2020 . 09 |
21 | Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: Real-world experience,2020台灣肝癌醫學會與台灣腫瘤消融醫學會聯合國際研討會,財團法人張榮發基金會國際會議中心11樓,2020.08.8 ~2020.08.9 , | 2020 . 08 |
22 | Predictive factors for incident or recurrent hepatocellular carcinoma in patients with chronic hepatitis C after direct-acting antiviral therapy,中華民國一O九年消化系聯合學術演講年會,國防醫學中心,2020.07.11~2020.07.12, | 2020 . 07 |
23 | Nivolumab for hepatocellular carcinoma: a combined experience at two hospitals in central Taiwan,中華民國一O九年消化系聯合學術演講年會,國防醫學中心,2020.07.11~2020.07.12, | 2020 . 07 |
24 | Kinetics in spleen stiffness values through elastography in patients with chronic hepatitis C on and off treatments with direct-acting antivirals,The 70th Annual Meeting of the American Association for the Study of Liver Diseases,Boston, MA, USA,2019.11.08~2019.11.12, | 2019 . 11 |
25 | Kinetics in Spleen Stiffness Values through Elastography in Patients with Chronic Hepatitis C on and off Treatments with Direct-acting Antivirals 接受Direct-acting Antivirals治療之慢性C型肝炎病患治療中及治療後脾臟硬度值變化之相關因子,2019 Taiwan Digestive Disease Week, TDDW,Kaohsiung Exhibition Center, Kaohsiung,2019.09.27~2019.09.29, | 2019 . 09 |
26 | Incidence of diabetes mellitus and long-term glycemic control in patients with chronic hepatitis C receiving direct-acting antiviral therapy,2019台灣消化系醫學週,高雄展覽館,2019.09.27~2019.09.29, | 2019 . 09 |
27 | Dynamic changes in glomerular filtration rate during and at 12 weeks after direct-acting antiviral therapy in patients with chronic hepatitis C,中華民國一○八年消化系聯合學術演講年會,國防醫學中心,2019.03.30~2019.03.31, | 2019 . 03 |
28 | Early and late Hepatitis B surface antigen declines predict treatment response to long-term nucleos(t)ide analogue Therapy in Chronic Hepatitis B patients,中華民國一○八年消化系聯合學術演講年會,國防醫學中心,2019.03.30~2019.03.31, | 2019 . 03 |
29 | 以治療前及治療後肝臟硬度測試預測慢性C型肝炎病患 接受抗病毒藥物治療後肝細胞癌之發生 Prediction of development of hepatocellular carcinoma using pretreatment and posttreatment liver stiffness measurements through elastography in patients treated for chronic hepatitis C,中華民國一○八年消化系聯合學術演講年會,國防醫學中心,2019.03.30~2019.03.31, | 2019 . 03 |
30 | 接受 Direct-acting Antivirals 治療之慢性C型肝炎病患 治療中治療後具有 肝臟硬度兩階段下降之現象 Two-phase declines in liver stiffness values through elastography in patients with chronic hepatitis C on and off treatments with direct-acting antivirals,中華民國一○八年消化系聯合學術演講年會,國防醫學中心,2019.03.30~2019.03.31, | 2019 . 03 |
31 | Real-world efficacy and safety of LDV/SOF treatment in HCV-1 and HCV-2 patients in Taiwan,中華民國一O八年消化系聯合學術演講年會,國防醫學中心,2019.03.30~2019.03.31, | 2019 . 03 |
32 | Distinct diagnostic performance for noninvasive fibrosis indices in patients with chronic hepatitis C before and after antiviral therapy,2018台灣消化系醫學週,臺大醫院國際會議中心,2018.09.29~2018.09.30, | 2018 . 09 |
33 | Insulin resistance and lipid profile in chronic hepatitis C patients treated with direct-acting antiviral agents,2018台灣消化系醫學週,台大醫院國際會議中心,2018.09.29~2018.09.30, | 2018 . 09 |
34 | Fatty metamorphosis increases liver stiffness and noninvasive indices of liver fibrosis in patients with chronic hepatitis C,2018台灣消化系醫學週,台大醫院國際會議中心,2018.09.29~2018.09.30, | 2018 . 09 |
35 | Direct-acting antiviral agents in hepatitis C patients with liver cirrhosis and Child-Pugh score ≥6,2018台灣消化系醫學週,台大醫院國際會議中心,2018.09.29~2018.09.30, | 2018 . 09 |
36 | Histology-based Comparisons of Liver Stiffness Values in Treatment-experienced Patients with Chronic Hepatitis C,2018 Taiwan Digestive Disease Week,NTUH International Convention Center, Taipei, Taiwan, ROC,2018.09.28~2018.09.30, | 2018 . 09 |
37 | Efficacy and Safety of Direct-Acting Antivirals in Treatment-naïve and-experienced Patients with Chronic Hepatitis C: a real-world preliminary result,2018 APASL Single Topic Conference on Hepatitis B Virus Taipei,Taipei International Convention Center (TICC),2018.06.22~2018.06.24, | 2018 . 06 |
38 | Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis C On and Off Treatment,2018 APASL Single Topic Conference on Hepatitis B Virus Taipei,Taipei International Convention Center, Taipei, Taiwan, ROC,2018.06.22~2018.06.24, | 2018 . 06 |
39 | SPLEEN STIFFNESS AND SPLENIC INDEX PREDICT ESOPHAGEAL VARICES IN PATIENTS WITH LIVER CIRRHOSIS,2018 APASL Single Topic Conference on Hepatitis B Virus Taipei,Taipei International Convention Center,2018.06.22~2018.06.24, | 2018 . 06 |
40 | 以ARFI肝臟硬度測試接受治療慢性C型肝炎病患於治療中及治療後具有顯著肝臟硬度下降之現象,中華民國一O七年台灣消化系聯合學術演講年會,台大醫院國際會議中心,2018.03.24~2018.03.25, | 2018 . 03 |
41 | Spleen stiffness and platelet count predict esophageal varices in patients with liver cirrhosis,中華民國一O七年台灣消化系聯合學術演講年會,台大醫院國際會議中心,2018.03.24~2018.03.25, | 2018 . 03 |
42 | 直接抗病毒藥物在初次治療或先前治療失敗之慢性C型肝炎病人之療效及安全性初步分析,中華民國107年台灣消化系聯合學術演講年會,台大醫學院國際會議中心,2018.03.24~2018.03.25, | 2018 . 03 |
43 | Efficacy and Safety of Direct-Acting Antivirals in Treatment-naïve and-experienced Patients with Chronic Hepatitis C: a real-world preliminary result,中華民國一O七年台灣消化系聯合學術演講年會,台大醫院國際會議中心,2018.03.24~2018.03.25, | 2018 . 03 |
44 | Long-term serum HBsAg kinetics in genotype B or C infected HBeAg-positive and –negative chronic hepatitis B patients following Pegasys therapy,2017台灣消化系醫學週,台大醫院國際會議中心,2017.09.30~2017.10.01, | 2017 . 09 |
45 | Changes of Renal Function During and After HCV Therapy with Peginterferon and Ribavirin and Its Influencing Factors,2017 台灣消化醫學週,台大醫院國際會議中心,2017.09.29~2017.10.01, | 2017 . 09 |
46 | Treatment with direct-acting anti-viral agents is associated with increased platelet counts in chronic hepatitis C patients without cirrhosis,2017台灣消化系醫學週,台大醫院國際會議中心,2017.09.30~2017.10.01, | 2017 . 09 |
47 | The combination of noninvasive assessment for liver fibrosis in chronic viral hepatitis by using modified FIB-4 and acoustic radiation force impulse: a single-center experience,2017 台灣消化醫學週,台大醫院國際會議中心,2017.09.29~2017.10.01, | 2017 . 09 |
48 | Comparison of non-invasive indices for the prediction of liver fibrosis in chronic viral hepatitis,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.03.18~2017.03.19, | 2017 . 03 |
49 | C型肝炎患者接受直接作用抗病毒藥物前後糖化血色素、血糖、胰島素阻抗、與血脂肪的變化,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.03.18~2017.03.19, | 2017 . 03 |
50 | Glycohemoglobin, sugar, insulin resistance, and lipid profile in chronic hepatitis C patients treated with direct-acting antiviral agents,中華民國一○六年消化系聯合學術演講年會,台中榮民總醫院,2017.03.18~2017.03.19, | 2017 . 03 |
51 | Comparison of non-invasive indices for the prediction of liver cirrhosis in chronic viral hepatitis,2016 TDDW 台灣消化醫學週,台北,2016.10.01~2016.10.02, | 2016 . 10 |
52 | Evolution and Predictive Role of Basal Core Promoter and Precore Mutants in Genotype B or C Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Undergoing Peginterferon Therapy,2016 TDDW 台灣消化醫學週,台北,2016.10.01~2016.10.02, | 2016 . 10 |
53 | Group-based trajectory model to predict hepatitis B surface antigen loss during nucleos(t)ide analogue therapy in chronic hepatitis B patients,2016 TDDW 台灣消化醫學週,台北,2016.10.01~2016.10.02, | 2016 . 10 |
54 | Long-term Serum HBsAg Kinetics in Chronic Hepatitis B Patients Who Achieve HBeAg Loss Following Pegasys Therapy,2016 APASL Single Topic Conference on Hepatitis C,Kaohsiung,2016.06.10~2016.06.10, | 2016 . 06 |
55 | Long-term Serum HBsAg Kinetics in Chronic Hepatitis B Patients Who Achieve HBeAg Loss Following Pegasys Therapy,中華民國一○五年消化系聯合學術演講年會,台北(台北榮民總醫院),2016.03.26~2016.03.27, | 2016 . 03 |
56 | 使用膠原蛋白面積比例定量肝臟纖維化: 慢性B型和C型肝炎之間的比較 Comparison of Collagen Proportionate Areas in Liver Fibrosis Quantification between Chronic Hepatitis B and C,中華民國一○五年消化系聯合學術演講年會,台北榮民總醫院,2016.03.27~2016.03.27,使用膠原蛋白面積比例定量肝臟纖維化: 慢性B型和C型肝炎之間的比較 | 2016 . 03 |
專書
暫無資料研究計畫
暫無資料專利技術
暫無資料獲獎事蹟
獲獎/Award (獲獎名稱,給獎單位,獲獎日期) |
日期 | |
1 | Outstanding Poster Award,台灣肝癌醫學會,2024.5.18 | 2024 . 05 |
2 | 2022 APASL-TOP 100 Outstanding Abstract,Asian Pacific Association for the Study of the Liver,2022.6.25 | 2022 . 06 |